Toggle navigation
Menu
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
73°
Search
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Local Weather
News
Sports
Entertainment
Calendar
Games
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Town & Gown
Subscribe
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Eiger Biopharma
(NQ:
EIGR
)
11.02
USD
-0.84 (-7.08%)
Official Closing Price
Updated: 6:03 PM EST, Jan 15, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All news about Eiger Biopharma
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Eiger Announces Sub-Analysis of Phase 2 Results Demonstrating High Response Rates to "All-Oral" Lonafarnib-Ritonavir Regimen in Low Viral Load HDV-Infected Patients at The International Liver Congress
April 17, 2018
Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced additional positive lonafarnib (LNF) data from the LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program presented at The...
From
PR Newswire
The Week Ahead In Biotech: PDUFA Dates, IPOs And More
April 06, 2018
Here's a few must-watch biotech catalysts this week. Conferences Panamerican League of Associations for Rheumatology Congress ...
Tags
Previews
NVS
Biotech
From
Benzinga
Eiger BioPharmaceuticals to Participate in Conferences in April
April 02, 2018
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that Eiger will participate at upcoming...
From
PR Newswire
Eiger Announces First Patient Dosed in Phase 2 PREVENT Study of Exendin 9-39 in Patients Suffering from Post-Bariatric Hypoglycemia
March 26, 2018
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, today announced the first patient dosed in PREVENT, a Phase 2,...
From
PR Newswire
BRIEF-Eiger Biopharmaceuticals Sees Phase 3 D-Livr Trial Starting In Second Half 2018?
March 21, 2018
* EIGER BIOPHARMACEUTICALS ANNOUNCES POSITIVE GUIDANCE FOLLOWING FDA MEETING ON HEPATITIS DELTA VIRUS REGISTRATION PROGRAM
Tags
companyNews
From
Reuters: Company News
Eiger BioPharmaceuticals Announces Positive Guidance Following FDA Meeting on Hepatitis Delta Virus Registration Program
March 21, 2018
- Phase 3 D-LIVR Trial Planned to Initiate in Second Half 2018
From
PR Newswire
46 Biggest Movers From Yesterday
March 12, 2018
Gainers BlueLinx Holdings Inc. (NYSE: BXC) shares gained 77.52 percent to close at $28.03 after the company reported a $413 ...
Tags
MARA
PICO
OGEN
From
Benzinga
32 Stocks Moving In Monday's Mid-Day Session
March 12, 2018
Gainers Arcadia Biosciences Inc (NASDAQ: RKDA) shares jumped 80.3 percent to $18.80. BlueLinx Holdings Inc. (NYSE: ...
Tags
MACK
Losers
CGNT
From
Benzinga
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
March 12, 2018
- Hepatitis Delta Virus Program Moving into Phase 3 in 2018
From
PR Newswire
Eiger BioPharmaceuticals to Participate in U.S. and International Investor and Partnership Conferences in March
March 06, 2018
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger,...
From
PR Newswire
Eiger Announces Abstracts and Presentations of LOWR HDV Program and Planned Registration Program at The International Liver Congress™ Meeting
March 05, 2018
Eiger BioPharmaceuticals, Inc., (NASDAQ: EIGR) today announced that abstracts from its LOWR HDV (LOnafarnib With Ritonavir in Hepatitis Delta Virus) Program will be presented at The International Liver...
From
PR Newswire
Eiger BioPharmaceuticals to Participate in Two Upcoming Investor Conferences in February
February 06, 2018
Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger,...
From
PR Newswire
Sum Up The Parts: IWC Could Be Worth $113
January 18, 2018
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and...
Tags
ETFs
From
ETF Channel
42 Biggest Movers From Yesterday
January 16, 2018
Gainers Spi Energy Co Ltd (ADR) (NASDAQ: SPI) climbed 63.75 percent to close at $1.04 on Tuesday after announcing ...
Tags
SRNE
RIOT
NEWA
From
Benzinga
Eiger BioPharmaceuticals reports disappointing study results
January 16, 2018
Eiger BioPharmaceuticals Inc. (Nasdaq: EIGR) reported disappointing results from a Phase 2 LIBERTY study in pulmonary arterial hypertension sending the stock price crashing $7.90 to close at $8.10....
From
MarketMinute.com Stock News
Eiger BioPharmaceuticals is Now Oversold (EIGR)
January 16, 2018
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a...
Tags
Stocks
From
Market News Video
Mid-Afternoon Market Update: U.S. Stocks Turn Negative; Energizer Shares Spike Higher
January 16, 2018
Toward the end of trading Tuesday, the Dow traded down 0.11 percent to 25,774.28 while the NASDAQ declined 0.48 percent to 7,226.49. The ...
Tags
ENR
Eurozone
Intraday Update
From
Benzinga
40 Stocks Moving In Tuesday's Mid-Day Session
January 16, 2018
Gainers Spi Energy Co Ltd (ADR) (NASDAQ: SPI) jumped 57.5 percent to $1.00 after announcing establishment of Blockchain-based ...
Tags
RXII
NNDM
ITUS
From
Benzinga
Mid-Day Market Update: Blackhawk Surges On News Of Acquisition By Silver Lake; Eiger Biopharmaceuticals Shares Slide
January 16, 2018
Midway through trading Tuesday, the Dow traded up 0.66 percent to 25,972.30 while the NASDAQ climbed 0.57 percent to 7,302.76. The ...
Tags
IO
Mid/Day Market Update
LPL
From
Benzinga
Mid-Morning Market Update: Markets Open Higher; Citigroup Profit Tops Expectations
January 16, 2018
Following the market opening Tuesday, the Dow traded up 1.02 percent to 26,066.25 while the NASDAQ climbed 0.89 percent to 7,325.93. The ...
Tags
EIGR
HAWK
Mid/Morning Market Update
From
Benzinga
Markets soar on upbeat earnings
January 16, 2018
Upbeat earnings sent the markets soaring to a sharply higher open with the Dow jumping 184 points to 25,987. Nasdaq gained 46 points to 7307.
Tags
Market News
From
MarketMinute.com Market Updates
Eiger BioPharmaceuticals Announces Phase 2 LIBERTY Study in Pulmonary Arterial Hypertension Did Not Meet Primary Endpoint
January 16, 2018
- End of Phase 2 Meeting Scheduled for HDV in February 2018
From
PR Newswire
3 Pharma and Biotech Stocks to Watch Out for in 2018
January 15, 2018
2017 turned out to be a pretty good year for pharma and biotech stocks with the Nasdaq Biotechnology index and the NYSE Arca Pharmaceutical index gaining 18.7% and 11.8%, respectively.
Tags
Stocks / Equities
Healthcare
Pharma/Biotech
From
Blogs - TalkMarkets
Eiger BioPharmaceuticals Announces Appointment of Commercial Operations Industry Veteran Eldon Mayer to its Board of Directors
January 08, 2018
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Eldon Mayer to its Board of Directors....
From
PR Newswire
Eiger BioPharmaceuticals Completes Enrollment of Phase 2 ULTRA Study of Ubenimex in Primary and Secondary Lymphedema Patients
January 04, 2018
- ULTRA Study Data Expected in Second Half 2018
From
PR Newswire
Eiger BioPharmaceuticals Appoints David Apelian, MD, PhD, MBA Chief Operating Officer and Executive Medical Officer
January 03, 2018
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of David Apelian, MD, PhD, MBA as Chief...
From
PR Newswire
Eiger BioPharmaceuticals to Present at Biotech Showcase™ 2018
January 02, 2018
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO, will...
From
PR Newswire
BRIEF-Eiger Biopharma Files For Mixed Shelf Of Up To $125 Mln
December 11, 2017
* EIGER BIOPHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $125 MILLION - SEC FILING Source text: (http://bit.ly/2nUkpvR) Further company coverage:
Tags
companyNews
From
Reuters: Company News
Eiger BioPharmaceuticals to Present at Jefferies 2017 Healthcare Conference
November 13, 2017
Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO of Eiger,...
From
PR Newswire
Eiger BioPharmaceuticals Reports Third Quarter 2017 Financial Results
November 09, 2017
-Clinical Results Planned in Each of Four Orphan Disease Programs by 4Q 2018
From
PR Newswire
< Previous
1
2
...
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.